166 related articles for article (PubMed ID: 27895793)
1. Evaluation of recurrent disease in the re-staging of colorectal cancer by
Chiaravalloti A; Fiorentini A; Palombo E; Rinino D; Lacanfora A; Danieli R; Di Russo C; Di Biagio D; Squillaci E; Schillaci O
Oncol Lett; 2016 Nov; 12(5):4209-4213. PubMed ID: 27895793
[TBL] [Abstract][Full Text] [Related]
2. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
[TBL] [Abstract][Full Text] [Related]
3. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
4. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
5. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
6. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.
Khan K; Athauda A; Aitken K; Cunningham D; Watkins D; Starling N; Cook GJ; Kalaitzaki E; Chau I; Rao S
Oncologist; 2016 Dec; 21(12):1502-1508. PubMed ID: 27742904
[TBL] [Abstract][Full Text] [Related]
8. Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations.
Zhang Y; Feng B; Zhang GL; Hu M; Fu Z; Zhao F; Zhang XL; Kong L; Yu JM
World J Gastroenterol; 2014 Jun; 20(21):6608-14. PubMed ID: 24914384
[TBL] [Abstract][Full Text] [Related]
9. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis.
Lu YY; Chen JH; Chien CR; Chen WT; Tsai SC; Lin WY; Kao CH
Int J Colorectal Dis; 2013 Aug; 28(8):1039-47. PubMed ID: 23407908
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of
Zhang XC; Zhang JH; Wang RF; Fan Y; Fu ZL; Yan P; Zhao GY; Bai YX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1071-1077. PubMed ID: 31848507
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Follow-up of Colorectal Cancer: Searching off Approaches Increasing Specificity for Detection of Recurrence.
Ince S; Okuyucu K; Hancerliogulları O; Alagoz E; San H; Arslan N
Radiol Oncol; 2017 Dec; 51(4):378-385. PubMed ID: 29333115
[TBL] [Abstract][Full Text] [Related]
13. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
Kyoto Y; Momose M; Kondo C; Itabashi M; Kameoka S; Kusakabe K
Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
[TBL] [Abstract][Full Text] [Related]
14. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
15. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
16. Clinical Value of Combining
Sookha RR; Zhi W; Shen Y; Lazare C; Wang L; Meng Y; Cao C; Hu J; Wu P
J Cancer; 2018; 9(17):3101-3108. PubMed ID: 30210633
[No Abstract] [Full Text] [Related]
17. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.
Özkan ZG; Has Şimşek D; Kuyumcu S; Oflas M; Işık EG; Doğan İ; Karabulut S; Şanlı Y
Ann Nucl Med; 2022 Jan; 36(1):52-60. PubMed ID: 34648169
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
